Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Nektar Therapeutics (NKTR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,640,379
  • Shares Outstanding, K 157,470
  • Annual Sales, $ 165,440 K
  • Annual Income, $ -153,520 K
  • 36-Month Beta 1.80
  • Price/Sales 52.55
  • Price/Cash Flow N/A
  • Price/Book 102.55

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.25 +56.22%
on 11/14/17
56.87 -0.42%
on 12/13/17
+19.53 (+52.64%)
since 11/13/17
3-Month
21.11 +168.26%
on 09/21/17
56.87 -0.42%
on 12/13/17
+34.87 (+160.25%)
since 09/13/17
52-Week
11.41 +396.32%
on 01/31/17
56.87 -0.42%
on 12/13/17
+44.39 (+362.66%)
since 12/13/16

Most Recent Stories

More News
Nektar Therapeutics to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / December 11, 2017 / Nektar Therapeutics (NASDAQ: NKTR) will be discussing their earnings results in their Q3 Earnings Call to be held on December 11, 2017 at 5:00 PM Eastern...

NKTR : 56.63 (+3.21%)
Today's Research Reports on Stocks to Watch: Sage Therapeutics and Nektar Therapeutics

NEW YORK, NY / ACCESSWIRE / December 8, 2017 / Sage Therapeutics headed higher on Thursday and hit a brand new high after announcing that its depressive disorder MDD treatment SAGE-217 had seen positive...

SAGE : 164.65 (+2.62%)
NKTR : 56.63 (+3.21%)
Can Nektar Therapeutics (NKTR) Run Higher on Strong Earnings Estimate Revisions?

Nektar Therapeutics (NKTR) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision, along with decent short-term momentum.

NKTR : 56.63 (+3.21%)
Analysis: Positioning to Benefit within Hertz Global, Cinedigm, Nektar Therapeutics, Akorn, Autodesk, and NextEra Energy Partners, LP -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Hertz Global Holdings, Inc...

CIDM : 1.51 (-1.31%)
ADSK : 106.02 (-0.29%)
NEP : 41.19 (+2.85%)
AKRX : 32.22 (+0.06%)
HTZ : 21.98 (+1.29%)
NKTR : 56.63 (+3.21%)
This Morning's Research Reports on Biotechnology Stocks -- FibroGen, Global Blood Therapeutics, Intercept Pharma, and Nektar Therapeutics

In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has issued free tailored Stock Review on FGEN, GBT, ICPT, and NKTR which is a click away at www.wallstequities.com/registration....

GBT : 38.35 (-0.13%)
FGEN : 44.15 (+1.03%)
ICPT : 64.20 (+5.87%)
NKTR : 56.63 (+3.21%)
Is the Options Market Predicting a Spike in Nektar (NKTR) Stock?

Investors in Nektar (NKTR) need to pay close attention to the stock based on moves in the options market lately.

NKTR : 56.63 (+3.21%)
Nektar (NKTR) Stock Up More than 300% This Year: Here's Why

Nektar's (NKTR) shares skyrocket in the year so far on a robust pipeline including several study initiations and strategic collaborations.

AZN : 33.57 (+0.45%)
MRK : 56.91 (-0.28%)
AMGN : 177.38 (+0.64%)
NKTR : 56.63 (+3.21%)
Phase III study with Amikacin Inhale in intubated and mechanically ventilated patients with Gram-negative pneumonia does not meet primary endpoint of superiority

Bayer today announced that INHALE, a global Phase III clinical study program investigating Amikacin Inhale in addition to standard of care in intubated and mechanically ventilated patients with Gram-negative...

NKTR : 56.63 (+3.21%)
Nektar Announces Key Executive Promotions to Drive the Continued Growth of the Company's Immuno-Oncology Pipeline

Nektar Therapeutics (Nasdaq: NKTR) announced today several promotions on its executive leadership team:

NKTR : 56.63 (+3.21%)
With Latest Update, FDA Approval Soon Could Send BTCY Ripping

Response to US FDA Request Met, BTCY Could be Right Around the Corner From an FDA Clearance by Year-End, Likelihood of Approval is High

EKSO : 2.32 (-9.38%)
F : 12.63 (+0.24%)
BTCY : 4.9500 (+43.48%)
BEAT : 28.15 (-0.53%)
IRTC : 51.85 (-0.56%)
NKTR : 56.63 (+3.21%)
BMY : 63.47 (+0.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to meet unmet medical needs and improve the benefits of drugs for patients. Its product pipeline consists...

See More

Key Turning Points

2nd Resistance Point 58.70
1st Resistance Point 57.66
Last Price 56.63
1st Support Level 54.80
2nd Support Level 52.98

See More

52-Week High 56.87
Last Price 56.63
Fibonacci 61.8% 39.50
Fibonacci 50% 34.14
Fibonacci 38.2% 28.78
52-Week Low 11.41

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.